MPL and autoimmune thrombocytopenic purpura: Yuan et al. (2019) screened an FDA-approved drug library that contained 1,528 drug compounds and identified five that inhibited SFTSV replication at concentrations of <10 μM, including two antibacterial and antifungal disinfectants (hexachlorophene and triclosan), a multi-kinase inhibitor for the treatment of advanced solid organ tumors (regorafenib), a small molecule agonist of the C-mannosylation of thrombopoietin receptor (c-Mpl) for the treatment of immune thrombocytopenic purpura and aplastic anemia (eltrombopag), and an antiprotozoal agent (broxyquinoline).